Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-12-18

Clinical Trial Update: Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) [Phase 3]

View source ↗

Summary

Phase 3 trial of avelumab in previously untreated epithelial ovarian cancer was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Avelumab (avelumab)

Snippet

Sponsor: Pfizer | Conditions: Ovarian Cancer | Phase 3 | Status: TERMINATED | Results posted: 2019-12-18